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Who should get hepatitis A vaccination?
■ Evidence summary
Infection with hepatitis A virus (HAV) is a
reportable illness in all 50 states, and it
continues to be one of the most reported
vaccine-preventable illnesses. The persist-
ence of extensive community-wide out-
breaks indicates that hepatitis A remains a
major public health problem. 
The costs associated with HAV are
substantial: 11% to 22% of individuals
with HAV are hospitalized, and adults
who become ill lose an average of 27 days
of work. The average cost of hepatitis A
ranges from $1817 to $2459 per case for
adults and $433 to $1492 for children. In
1989, the estimated annual direct and indi-
rect costs of HAV in the United States were
more then $300 million (in 1997 dollars).1
Hepatitis A can produce either asymp-
tomatic or symptomatic infection in humans
after an average incubation period of 28
days. The illness is usually marked by a sud-
den onset of symptoms including fever,
malaise, nausea, anorexia, abdominal 
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C L I N I C A L C O M M E N T A R Y
Anyone who does not want to get 
hepatitis A should receive the vaccine
A good information master needs to know his
resources. The question posed in this clinical
inquiry is a good example. Questions about who
should receive which vaccine are determined by
the Advisory Committee on Immunization
Practices, and their recommendations are 
available on the CDC’s web site (www.cdc.gov/nip/
publications/acip-list.htm). 
With that said, anyone who does not want to get
hepatitis A should receive the vaccine. Hepatitis A
is the most common vaccine preventable disease,
which on occasion can be severe, especially in
adults. The vaccine has no serious side effects, is
highly effective and, if widely adopted, would 
dramatically decrease the incidence of hepatitis A
in the population. 
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The following groups are at increased risk of 
contracting or having severe outcomes from 
hepatitis A and should receive vaccination.
• Persons traveling to or working in countries
that have high or intermediate rates of infection.
Specific country recommendations are available at
www.cdc.gov/travel/destinat.htm (strength 
of recommendation [SOR]: B)
• Men who have sex with men (SOR: B)
• Illegal-drug users (whether drug is injected 
or not) (SOR: B)
• Persons who have occupational risk for 
infection (eg, research settings working with 
nonhuman primates) (SOR: C)
• Persons with clotting-factor disorders (SOR: C)
• Persons with chronic liver disease (SOR: B)
• Children (age 2 to 18) living in states, counties,
and communities where rates of hepatitis A are at
least twice the national average. These states
include: Alaska, Arizona, California, Idaho, Nevada,
New Mexico, Oklahoma, Oregon, South Dakota,
Utah, and Washington. The rates of hepatitis A for
individual counties can be found at the Centers for
Disease Control and Prevention (CDC) web site
(www.cdc.gov/ncidod/diseases/hepatitis/a/vax/index.
htm). Consider giving hepatitis A vaccine to children
(age 2 to 18) in areas with rates greater than the
national average but less than twice the national
average. These states include Arkansas, Colorado,
Missouri, Montana, Texas, and Wyoming (SOR: B).
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Hepatitis A 
vaccine is highly
effective, and, 
if widely 
adopted, would 
dramatically
decrease the 
incidence of 
the disease
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discomfort, jaundice, and dark urine. The
illness usually lasts less than 2 months.
Though not usually life threatening, an esti-
mated 100 deaths annually are attributed to
acute liver failure due to hepatitis A. Patients
with chronic liver disease may be at higher
risk of developing fulminant hepatitis A.2,3
The likelihood of symptomatic disease is
directly related to age, with 70% of adults
developing jaundice and most infections in
children aged <6 years having no symptoms.
HAV is transmitted primarily from
fecal-oral route by either person-to-person
contact or ingestion of fecally contaminat-
ed food or water. Although rare, it is possi-
ble for transmission by blood or blood
products collected from donors during the
viremic phase of their infection. Although
HAV has been detected in saliva, transmis-
sion by saliva has not been demonstrated.
Under the right conditions HAV can be sta-
ble in the environment for months. Heating
foods to >185° F for 1 minute or disinfect-
ing surfaces with 1:100 dilution of bleach
in tap water is necessary to inactivate HAV.1
Vaccination against HAV is recom-
mended for those at high risk for contract-
ing the illness or for any person wishing to
obtain immunity. Prospective studies indi-
cate that persons traveling in areas with
high rates of HAV are themselves at 44
times increased risk.4 Among men who
have sex with men, numerous cohort stud-
ies reveal increased rates of infection due
to anal-oral sexual practices and higher
number of sexual partners.5–7 Intravenous
drug users and non-IV illicit drug users are
both at increased risk of HAV infection.8–10
In the United States, children living in
states with increased HAV incidence rates
are also considered to be at high risk.1 Less
strong evidence exists for vaccinating
those with occupational hazards (for
example, working in a research setting
with nonhuman primates) or persons with
clotting factor disorders.11,12
A corollary question is who does not
routinely need hepatitis A vaccine. In gen-
eral, food service workers, sewerage work-
ers, healthcare workers, children aged <2
years, day-care attendees, and residents of
institutions for the developmentally dis-
abled do not need routine immunization
The currently licensed inactivated hep-
atitis A vaccines are highly immunogenic
and clinically effective in children 2 to 18
years and in adults. In a double-blind, con-
trolled, randomized study of 1000 children
in New York revealed clinical efficacy of
100%.13 A second study of 40,000 children
in Thailand had a clinical efficacy of
94%.13 Numerous other studies have 
supported findings of near 100% immuno-
genicity in all age groups and clinical 
efficacy in all age groups.1
R E F E R E N C E S
1. Prevention of hepatitis A through active or passive
immunization. Recommendations of the Advisory
Committee on Immunization Practices (ACIP). MMWR
Recomm Rep 1999; 48(RR-12):1–37.
2. Vento S, Garofano T, Renzini C, et al. Fulminant hepa-
titis associated with hepatitis A virus superinfection in
patients with chronic hepatitis C. N Engl J Med 1998;
338:286–290.
3. Keeffe EB. Is hepatitis A more severe in patients with
chronic hepatitis B and other chronic liver diseases?
Am J Gastroenterol 1995; 90:201–205.
4. Steffen R, Rickenbach M, Wilhelm U, Helminger A,
Schar M. Health problems after travel to developing
countries. J Infect Dis 1987; 156:84–91.
5. Villano SA, Nelson KE, Vlahov D, Purcell RH, Saah AJ,
Thomas DL. Hepatitis A among homosexual men and
injection drug users: more evidence for vaccination.
Clin Infect Dis 1997; 25:726–728.
6. Henning KJ, Bell E, Braun J, Barker ND. A community-
wide outbreak of hepatitis A: risk factors for infection
among homosexual and bisexual men. Am J Med
1995; 99:132–136.
7. Corey L, Holmes KK. Sexual transmission of hepatitis
A in homosexual men: incidence and mechanism. 
N Engl J Med 1980; 302:435–438.
8. Bell BP, Shapiro CN, Alter MJ, et al. The diverse pat-
terns of hepatitis A epidemiology in the United
States—implication for vaccination strategies. J Infect
Dis 1998; 178:1579–1584.
9. Schade CP, Komorwska D. Continuing outbreak of hep-
atitis A linked with intravenous drug abuse in
Multnomah County. Public Health Rep 1988;
103:452–459.
10. Harkess J, Gildon B, Istre GR. Outbreaks of hepatitis A
among illicit drug users, Oklahoma, 1984–87. Am J
Public Health 1989; 79:463–466.
11. Hinthorn DR, Foster MT Jr., Bruce HL, Aach RD. An
outbreak of chimpanzee associated hepatitis. J Occup
Med 1974; 16:388–391.
12. Mannucci PM, Gdovin S, Gringeri A, et al.
Transmission of hepatitis A to patients with hemophil-
ia by factor VIII concentrates treated with organic sol-
vent and detergent to inactivate viruses. The Italian
Collaborative Group. Ann Intern Med 1994; 120:1–7.
13. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T,
Poopatanakool W, Kozik CA et al. Protection against
hepatitis A by an inactivated vaccine. JAMA 1994;
271:1328–1334.
